BioCatalystWatch
VYGRWorkspace / VYGR / OverviewCompany library
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. (VYGR)

Website

Price
Market cap
Next catalystExpected Q4 2026VY7523 — MAD study in early Alzheimer’s disease · Phase 1 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

VY7523

Pathological tau

PreINDP1P2P3FilingApproved
Upcoming / outlook

VY1706

MAPT (tau) mRNA × ALPL

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

ALPL-VYGR-NeuroShuttle

ALPL

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ALPL-VYGR-NeuroShuttle

ALPL

PreINDP1P2P3FilingApproved
Upcoming / outlook

VY7523

Pathological tau

PreINDP1P2P3FilingApproved
Upcoming / outlook

VY1706

MAPT (tau) mRNA × ALPL

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

Ab03

Antibody

Pathological tau

PreINDP1P2P3FilingApproved
VCAP-101

ALPL

PreINDP1P2P3FilingApproved
VCAP-100

PreINDP1P2P3FilingApproved
VCAP-337

PreINDP1P2P3FilingApproved
VCAP-102

ALPL

PreINDP1P2P3FilingApproved
Ab04

Antibody

Pathological tau

PreINDP1P2P3FilingApproved
VCAP-336

PreINDP1P2P3FilingApproved
VCAP-290

PreINDP1P2P3FilingApproved
SOD1 gene therapy

Gene therapy

PreINDP1P2P3FilingApproved
GBA1

PreINDP1P2P3FilingApproved

Partner / License out

Gene therapy

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Small molecule

TDP-43

Gene therapy

Upcoming / outlook

TDP-43

Small molecule

TDP-43

IND

PreINDP1P2P3FilingApproved

History / paused

PreINDP1P2P3FilingApproved

SOD1

PreINDP1P2P3FilingApproved

SOD1 mRNA

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status
3M

Market Reaction / Supply Context

Market Structure

VYGR PR & News

PR & News

VYGR SEC archive